Marshall & Sullivan Inc. WA trimmed its position in Thermo Fisher Scientific Inc (NYSE:TMO) by 0.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,860 shares of the medical research company’s stock after selling 69 shares during the quarter. Thermo Fisher Scientific makes up approximately 2.1% of Marshall & Sullivan Inc. WA’s portfolio, making the stock its 22nd largest position. Marshall & Sullivan Inc. WA’s holdings in Thermo Fisher Scientific were worth $2,418,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. BB&T Securities LLC boosted its holdings in shares of Thermo Fisher Scientific by 4.4% in the first quarter. BB&T Securities LLC now owns 89,837 shares of the medical research company’s stock worth $13,798,000 after buying an additional 3,819 shares during the period. State Board of Administration of Florida Retirement System boosted its holdings in shares of Thermo Fisher Scientific by 0.9% in the second quarter. State Board of Administration of Florida Retirement System now owns 580,712 shares of the medical research company’s stock worth $101,317,000 after buying an additional 5,213 shares during the period. Mitchell Capital Management Co. boosted its holdings in shares of Thermo Fisher Scientific by 40.3% in the second quarter. Mitchell Capital Management Co. now owns 44,940 shares of the medical research company’s stock worth $7,841,000 after buying an additional 12,910 shares during the period. Toronto Dominion Bank boosted its holdings in shares of Thermo Fisher Scientific by 53.5% in the first quarter. Toronto Dominion Bank now owns 107,099 shares of the medical research company’s stock worth $16,450,000 after buying an additional 37,307 shares during the period. Finally, IBM Retirement Fund boosted its holdings in shares of Thermo Fisher Scientific by 117.7% in the second quarter. IBM Retirement Fund now owns 9,537 shares of the medical research company’s stock worth $1,860,000 after buying an additional 5,157 shares during the period. Institutional investors own 83.36% of the company’s stock.

TMO has been the subject of several research reports. Zacks Investment Research cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Tuesday, September 12th. Leerink Swann raised their price target on shares of Thermo Fisher Scientific from $190.00 to $207.00 and gave the stock an “outperform” rating in a report on Monday. Cowen and Company restated an “outperform” rating and set a $220.00 price target (up from $200.00) on shares of Thermo Fisher Scientific in a report on Sunday, September 10th. Barclays PLC restated an “overweight” rating and set a $215.00 price target (up from $200.00) on shares of Thermo Fisher Scientific in a report on Monday, September 25th. Finally, Goldman Sachs Group, Inc. (The) started coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, September 26th. They set a “buy” rating and a $225.00 price objective on the stock. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $203.64.

In other news, SVP Gregory J. Herrema sold 30,000 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, August 2nd. The stock was sold at an average price of $176.02, for a total transaction of $5,280,600.00. Following the sale, the senior vice president now directly owns 67,016 shares of the company’s stock, valued at $11,796,156.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jim P. Manzi sold 1,000 shares of Thermo Fisher Scientific stock in a transaction dated Thursday, August 17th. The shares were sold at an average price of $175.20, for a total value of $175,200.00. Following the sale, the director now directly owns 38,757 shares in the company, valued at $6,790,226.40. The disclosure for this sale can be found here. Insiders sold 52,738 shares of company stock worth $9,302,112 over the last ninety days. 0.49% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY WARNING: This news story was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another domain, it was copied illegally and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/10/11/thermo-fisher-scientific-inc-tmo-holdings-lowered-by-marshall-sullivan-inc-wa.html.

Shares of Thermo Fisher Scientific Inc (TMO) opened at 192.64 on Wednesday. The firm has a market cap of $75.15 billion, a P/E ratio of 33.56 and a beta of 1.05. Thermo Fisher Scientific Inc has a 1-year low of $139.07 and a 1-year high of $194.30. The firm’s 50-day moving average is $187.80 and its 200-day moving average is $174.71.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.27 by $0.03. The company had revenue of $5 billion for the quarter, compared to analyst estimates of $4.92 billion. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. Thermo Fisher Scientific’s quarterly revenue was up 10.2% on a year-over-year basis. During the same period in the prior year, the firm posted $2.03 EPS. On average, analysts anticipate that Thermo Fisher Scientific Inc will post $9.35 EPS for the current fiscal year.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Stock Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related stocks with our FREE daily email newsletter.